What is the current Price Target for the Akero Therapeutics Inc stock?

The average Akero Therapeutics Inc target price is $77.64. This is 94.14% higher than the current stock price. The highest price target is 172.57%, the lowest is 50.04%. 11 Analysts have issued a price target Akero Therapeutics Inc 2026 .

How high will the Akero Therapeutics Inc stock rise?

No reliable answer can be given as to how high the Akero Therapeutics Inc stock will rise. The performance of stocks, including the Akero Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Akero Therapeutics Inc stock today?

The performance of Akero Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Akero Therapeutics Inc stock fall?

The decline in Akero Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Akero Therapeutics Inc Forecast, price target & analysts

$37.70

5.74% today

Nasdaq, Apr 04, 07:49 pm CET

ISIN

US00973Y1082

Symbol

AKRO

Reports

Quarter | Annual

Index

NASDAQ Composite

Overview Dividends Analysts Charts News Strategies

Akero Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Akero Therapeutics Inc Classifications & Recommendation:

Buy

100%

Akero Therapeutics Inc Price Target

Target Price	$77.64
Price	$39.99
Potential	94.14% register free of charge
Number of Estimates	11

	11 Analysts have issued a price target Akero Therapeutics Inc 2026 . The average Akero Therapeutics Inc target price is $77.64. This is 94.14% register free of charge higher than the current stock price. The highest price target is $109.00 172.57% register free of charge , the lowest is $60.00 50.04% register free of charge .
	A rating was issued by 12 analysts: 12 Analysts recommend Akero Therapeutics Inc to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Akero Therapeutics Inc stock has an average upside potential 2026 of 94.14% register free of charge . Most analysts recommend the Akero Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-3.75	-4.49
	29.76%	19.73%
P/E		negative

5 Analysts have issued a Akero Therapeutics Inc forecast for earnings per share. The average Akero Therapeutics Inc EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-3.75	29.76%
2025	$-4.49 19.73% Unlock
2026	$-4.79 6.68% Unlock
2027	$-4.69 2.09% Unlock
2028	$-3.81 18.76% Unlock
2029	$-1.05 72.44% Unlock

Current	-10.67	20.56%
2025	-8.90 16.59% Unlock
2026	-8.35 6.18% Unlock
2027	-8.53 2.16% Unlock
2028	-10.50 23.09% Unlock
2029	-38.09 262.76% Unlock

Akero Therapeutics Inc...

Current Akero Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 03 2025
UBS	Locked ➜ Locked	Locked	Jan 31 2025
B of A Securities	Locked ➜ Locked	Locked	Jan 30 2025
Canaccord Genuity	Locked ➜ Locked	Locked	Jan 28 2025
Citigroup	Locked ➜ Locked	Locked	Jan 28 2025
Morgan Stanley	Locked ➜ Locked	Locked	Jan 28 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Jan 27 2025

Analyst Rating	Date
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 03 2025
Locked UBS: Locked ➜ Locked	Jan 31 2025
Locked B of A Securities: Locked ➜ Locked	Jan 30 2025
Locked Canaccord Genuity: Locked ➜ Locked	Jan 28 2025
Locked Citigroup: Locked ➜ Locked	Jan 28 2025
Locked Morgan Stanley: Locked ➜ Locked	Jan 28 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Jan 27 2025

Discover more stocks with a high price target

Novo Nordisk 83.92%

Coinbase Global, Inc. 83.53%

BioNTech SE - ADR 50.09%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now